• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Structure Therapeutics Inc. - American Depositary Shares (NQ: GPCR )

    36.30 -0.32 (-0.87%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,076,265
    Open 36.37
    Bid (Size) 35.20 (1)
    Ask (Size) 37.25 (1)
    Prev. Close 36.62
    Today's Range 34.83 - 37.10
    52wk Range 26.61 - 75.02
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
    The analyst is closely watching MariTide, a potential monthly injection to treat obesity. 
    Via Investor's Business Daily
    As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
    Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention. 
    Via Investor's Business Daily

    Performance

    YTD
    -10.13%
    -10.13%
    1 Month
    -9.25%
    -9.25%
    3 Month
    -18.72%
    -18.72%
    6 Month
    -4.02%
    -4.02%
    1 Year
    -45.04%
    -45.04%

    More News

    Read More
    Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO
    Via Investor's Business Daily
    Peering Into Structure Therapeutics's Recent Short Interest
    Via Benzinga
    Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
    Via MarketBeat
    Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
    Via Investor's Business Daily
    The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
    Via Investor's Business Daily
    Structure Therapeutics Appoints Angus C. Russell to Board of Directors
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    Structure Therapeutics Announces Participation in Upcoming Investor Conferences
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    3 Promising Biotech Stocks for the Long-Term: August 2024
    Via InvestorPlace
    GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q2 2024
    Via InvestorPlace
    Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    3 Biotech Stocks That Could Make Your Summer Unforgettable
    Via InvestorPlace
    Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.
    Via The Motley Fool
    Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
    Via Investor's Business Daily
    Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
    Via Benzinga
    ASML Reports Q2 Results, Joins Spirit Airlines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    The 3 Most Undervalued Biotech Stocks to Buy in July 2024
    Via InvestorPlace
    Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
    Via MarketBeat
    Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
    Via MarketBeat
    Exposures Product Safety
    Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
    Via MarketBeat
    The 3 Smartest Biotech Stocks to Buy With $5K Right Now
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.